885 related articles for article (PubMed ID: 29802219)
21. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction.
Andres MS; Ramalingam S; Rosen SD; Baksi J; Khattar R; Kirichenko Y; Young K; Yousaf N; Okines A; Huddart R; Harrington K; Furness AJS; Turajlic S; Pickering L; Popat S; Larkin J; Lyon AR
Cardiooncology; 2022 Nov; 8(1):21. PubMed ID: 36424659
[TBL] [Abstract][Full Text] [Related]
22. Review: Treatment of immune checkpoint inhibitor-associated myocarditis.
Heemelaar JC; Antoni ML; Neilan TG
J Cardiovasc Pharmacol; 2023 Aug; ():. PubMed ID: 37506676
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
24. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
[TBL] [Abstract][Full Text] [Related]
25. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.
Paluri RK; Pulipati Y; Regalla DKR
Oncol Rev; 2023; 17():11456. PubMed ID: 38045806
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.
Kuhnly NM; Coviello J
Clin J Oncol Nurs; 2022 Feb; 26(1):54-60. PubMed ID: 35073300
[TBL] [Abstract][Full Text] [Related]
29. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
[TBL] [Abstract][Full Text] [Related]
30. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
[TBL] [Abstract][Full Text] [Related]
31. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis.
Quinaglia T; Gongora C; Awadalla M; Hassan MZO; Zafar A; Drobni ZD; Mahmood SS; Zhang L; Coelho-Filho OR; Suero-Abreu GA; Rizvi MA; Sahni G; Mandawat A; Zatarain-Nicolás E; Mahmoudi M; Sullivan R; Ganatra S; Heinzerling LM; Thuny F; Ederhy S; Gilman HK; Sama S; Nikolaidou S; Mansilla AG; Calles A; Cabral M; Fernández-Avilés F; Gavira JJ; González NS; García de Yébenes Castro M; Barac A; Afilalo J; Zlotoff DA; Zubiri L; Reynolds KL; Devereux R; Hung J; Picard MH; Yang EH; Gupta D; Michel C; Lyon AR; Chen CL; Nohria A; Fradley MG; Thavendiranathan P; Neilan TG
JACC Cardiovasc Imaging; 2022 Nov; 15(11):1883-1896. PubMed ID: 36357131
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution.
Qin Y; Zhang T; Du Z; Chen S; Li Y; Lv Y; Du X; Hu Y; Liu Z
Int Immunopharmacol; 2024 Jul; 136():112385. PubMed ID: 38850788
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.
Puzanov I; Subramanian P; Yatsynovich YV; Jacobs DM; Chilbert MR; Sharma UC; Ito F; Feuerstein SG; Stefanovic F; Switzer B; Hicar MD; Curtis AB; Spangenthal EJ; Dy GK; Ernstoff MS; Vachhani P; Page BJ; Agrawal N; Khunger A; Kapoor A; Hattoum A; Schentag JJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34162715
[TBL] [Abstract][Full Text] [Related]
34. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
[TBL] [Abstract][Full Text] [Related]
35. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
36. T cells specific for α-myosin drive immunotherapy-related myocarditis.
Axelrod ML; Meijers WC; Screever EM; Qin J; Carroll MG; Sun X; Tannous E; Zhang Y; Sugiura A; Taylor BC; Hanna A; Zhang S; Amancherla K; Tai W; Wright JJ; Wei SC; Opalenik SR; Toren AL; Rathmell JC; Ferrell PB; Phillips EJ; Mallal S; Johnson DB; Allison JP; Moslehi JJ; Balko JM
Nature; 2022 Nov; 611(7937):818-826. PubMed ID: 36385524
[TBL] [Abstract][Full Text] [Related]
37. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
38. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
40. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
